Chronic treatment with antiseizure medications (ASMs) are associated with several adverse effects including metabolic and hormonal dysfunctions and increased cardio vascular risk in persons with epilepsy (PWE) [1]. A recent study reported that the adjusted hazard ratio of diabetes in the epileptic patients was 1.31 compared to the non-epileptic population [2]. In PWE, valproate (VPA) is a commonly prescribed conventional ASM and among the newer ASM, levetiracetam (LEV) is widely prescribed in recent year [3–5].
4
AGO
AGO
0